NCT05656027 - Phase 3 Evaluation of the Safety and Efficacy of LNZ101 for the Treatment of Presbyopia | Biotech Hunter

Enrollment

469

Participants

Timeline

Start Date

December 19, 2022

Primary Completion Date

December 15, 2023

Study Completion Date

January 25, 2024

Conditions

PresbyopiaRefractive ErrorNear VisionMiosisEye Diseases

Interventions

DRUG

Aceclidine + Brimonidine

LNZ101 (Aceclidine/Brimonidine) ophthalmic solution

DRUG

Aceclidine

LNZ100 Aceclidine ophthalmic solution

DRUG

Brimonidine

Brimonidine ophthalmic solution

Trial Locations (20)

18704

Site #103, Kingston

32757

Site #102, Mt. Dora

37167

Site #112, Smyrna

38104

Site #116, Memphis

58103

Site #104, Fargo

61201

Site #118, Rock Island

66762

Site #108, Pittsburg

78229

Site #119, San Antonio

Site #123, San Antonio

80120

Site #109, Littleton

85032

Site #122, Phoenix

85053

Site #124, Phoenix

85202

Site #121, Mesa

85224

Site #106, Chandler

85351

Site #125, Sun City

91204

Site #101, Glendale

92843

Site #110, Garden Grove

93105

Site #111, Santa Barbara

94954

Site #107, Petaluma

95670

Site #126, Rancho Cordova